Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

Detailed price information for Covenant Logistics Group Inc (CVLG-N) from The Globe and Mail including charting and trades.

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

The announcement adds to a string of setbacks in Pfizer’s bid to win a slice of the booming market that Wall Street projects to be worth $150 billion.

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

LifeMD's growth accelerates with expanded insurance, new health products, and a 43% revenue boost. Click here to read our ...

Lilly claims Premier Weight Loss is selling altered versions of Lilly's weight loss drugs Zepbound and Mounjaro. In the lawsuit, Lilly alleges Premier Weight Loss is falsely marketing Lilly's products ...

Medicare coverage for anti-obesity drugs was not finalized, affecting drugs like Wegovy and Zepbound. Covering weight loss drugs may cost $35 billion from 2026–2034, with estimated savings under ...